Medigene AG: Medigene participates at upcoming conferences

Martinsried/Munich (pta006/08.04.2019/07:30 UTC+2) Medigene AG (FSE: MDG1, Prime Standard) today announced its participation at the following upcoming networking and scientific conferences:

Deutsche Biotechnologietage 2019
Date: 09 - 10 April 2019
Location: Würzburg, Germany
Dr Kai Pinkernell, Chief Medical Officer (CMO) and Chief Development Officer (CDO) of Medigene AG, will give a talk entitled "Developments of T cell therapies in the field of Immunotherapies" during the symposium "Experiences with gene therapeutics - from development to approval" on 10 April 2019 from 11.30 am to 13.00 pm.

Needham & Company 18th Annual Healthcare Conference 2019
Date: 09 - 10 April 2019
Location: New York, USA
Prof. Dolores J. Schendel, CEO of Medigene AG, will give a company presentation on 10 April 2019 at 4.10 pm.

ITOC6 Conference
Date: 11 - 13 April 2019
Location: Vienna, Austria

3rd Annual European NeoAg Summit
Date: 23 - 25 April 2019
Location: Amsterdam, Netherlands

22nd ASGCT Annual Meeting
Date: 29 April - 02 May 2019
Location: Washington, USA
Dr Maja Buerdek, Director Cellular Tools at Medigene, will give an oral presentation on the topic "In Vitro Evaluation of Potential PRAME TCR-Mediated Off-Target Toxicity Using iPSC-Derived Neuronal Cells" on 30 April 2019 from 5.00pm - 5.15pm in the session Nonclinical Studies and Assay Development.

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 33 3301
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate